orx142
·Code: ORX142
orx142: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Centessa Pharmaceuticals plc (CNTA) | Phase 1 |
FDA Decisions
FDA_MeetingFDA cleared the IND to initiate a first-in-human Phase 1 study of ORX142 in healthy volunteers for select neurological and neurodegenerative disorders to assess safety, tolerability and PK.(CNTA)
Frequently asked questions
Who is developing orx142?
orx142 is being developed by Centessa Pharmaceuticals plc.
What is orx142's latest FDA decision?
The most recent tracked FDA decision for orx142 is FDA_Meeting for FDA cleared the IND to initiate a first-in-human Phase 1 study of ORX142 in healthy volunteers for select neurological and neurodegenerative disorders to assess safety, tolerability and PK., dated June 16, 2025.
Get deeper analysis on orx142
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis